Puma Biotechnology (PBYI) Free Cash Flow (2010 - 2026)

Puma Biotechnology's Free Cash Flow history runs 17 years deep, the most recent figure standing at $15.4 million for Q1 2026.

• Quarterly Free Cash Flow rose 334.13% year-over-year to $15.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.6 million (up 71.96% YoY) and the FY2025 annual result came in at $41.7 million, up 7.38% from the prior year.
• Free Cash Flow was $15.4 million for Q1 2026 at Puma Biotechnology, up from $14.5 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $17.3 million in Q3 2022 and bottomed at -$26.9 million in Q1 2022.
• A 5-year average of $6.3 million and a median of $10.4 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow plunged 18648.65% — and 2025, when it soared 1289.68%.
• Puma Biotechnology's Free Cash Flow stood at $7.7 million in 2022, then jumped by 35.74% to $10.4 million in 2023, then surged by 49.3% to $15.6 million in 2024, then dropped by 7.17% to $14.5 million in 2025, then advanced by 6.65% to $15.4 million in 2026.
• Business Quant data shows PBYI's Free Cash Flow at $15.4 million in Q1 2026, $14.5 million in Q4 2025, and $9.6 million in Q3 2025.